Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 14/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2049299 | 0.84 | CASP1 (0.39) | SMN1; SMN2CASP1MAPTALDH1A1 | |
| SCHEMBL14943742 | 0.84 | SMN1; SMN2 (0.38) | SMN1; SMN2CASP1MAPTALDH1A1TSHR | |
| SCHEMBL731986 | 0.84 | CASP1 (0.39) | SMN1; SMN2CASP1MAPTALDH1A1 | |
| SCHEMBL12401070 | 0.83 | SMN1; SMN2 (0.37) | SMN1; SMN2CASP1MAPTALDH1A1TSHR | |
| SCHEMBL15338738 | 0.83 | SMN1; SMN2 (0.37) | SMN1; SMN2CASP1MAPTALDH1A1TSHR | |
| SCHEMBL14865101 | 0.78 | CA1 (0.33) | — | |
| SCHEMBL12175008 | 0.78 | CA1 (0.33) | — | |
| SCHEMBL12503784 | 0.77 | ALOX15 (0.37) | SMN1; SMN2TSHR | |
| SCHEMBL12468221 | 0.75 | CA1 (0.50) | — | |
| SCHEMBL12482274 | 0.75 | CA1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | SMN1; SMN2 2265/4885CASP1 122/4885MAPT 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.